Dermatologic adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex.

Systemic inhibitors of mechanistic target of rapamycin (mTOR) have antiproliferative, antiangiogenic, and immunosuppressive properties. In dermatology, they are effective for managing certain vascular anomalies and genodermatoses, notably tuberous sclerosis complex (TSC).1 Compared to cancer patients or transplant recipients, TSC patients are prescribed mTOR inhibitors at lower doses and their treatment regimens are less likely to include other drugs that may induce similar side effects.

Click here to read the full article @ The British journal of dermatology